CIDARA THERAPEUTICS, INC. (NASDAQ:CDTX) Files An 8-K Regulation FD Disclosure

Item7.01

On January9, 2017, the slide presentation attached as Exhibit
99.1 will be presented in various investor meetings by the
management of Cidara Therapeutics, Inc. (the Company).
Information from this slide presentation may also be used by the
management of the Company in future meetings regarding the
Company.

The information contained in this Item 7.01 and in Exhibit 99.1
of this Current Report on Form 8-K shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference
in such a filing.

(d) Exhibits.

1

About CIDARA THERAPEUTICS, INC. (NASDAQ:CDTX)

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease.

CIDARA THERAPEUTICS, INC. (NASDAQ:CDTX) Recent Trading Information

CIDARA THERAPEUTICS, INC. (NASDAQ:CDTX) closed its last trading session down -0.15 at 10.45 with 14,771 shares trading hands.